iohexol has been researched along with Apolipoprotein B-100, Familial Defective in 3 studies
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paclitaxel tissue uptake was assessed in 20 iliofemoral arteries of a domestic swine." | 1.39 | Tissue uptake, distribution, and healing response after delivery of paclitaxel via second-generation iopromide-based balloon coating: a comparison with the first-generation technology in the iliofemoral porcine model. ( Afari, ME; Buszman, PP; Conditt, GB; Granada, JF; Kaluza, GL; McGregor, JC; Peppas, A; Rousselle, SD; Stenoien, M; Tellez, A, 2013) |
| "Heterozygous familial hypercholesterolemia (HeFH) can be associated with early coronary artery disease (CAD) in asymptomatic patients." | 1.39 | Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolemia and null allele low-density lipoprotein receptor mutations. ( Alomar Serrallach, X; Barros Membrilla, A; Cardona Olle, M; Carreras Costa, F; Franco Peral, M; Hidalgo Perez, JA; Leta Petracca, R; Pons-Lladó, G; Pujadas Olano, S; Viladés Medel, D, 2013) |
| "Homozygous familial hypercholesterolemia (HoFH) is a rare disorder characterized by the early onset of atherosclerosis and usually occurs at the ostia of coronary arteries." | 1.36 | Evaluation of coronary flow velocity reserve in homozygous familial hypercholesterolemia by transthoracic Doppler echocardiography and dual-source computed tomography. ( Li, R; Li, Z; Lin, J; Ren, H; Wang, L; Wang, Z; Yang, Y; Yu, W; Zhang, X; Zhang, Z, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buszman, PP | 1 |
| Tellez, A | 1 |
| Afari, ME | 1 |
| Peppas, A | 1 |
| Conditt, GB | 1 |
| Rousselle, SD | 1 |
| McGregor, JC | 1 |
| Stenoien, M | 1 |
| Kaluza, GL | 1 |
| Granada, JF | 1 |
| Yang, Y | 1 |
| Zhang, X | 1 |
| Li, R | 1 |
| Ren, H | 1 |
| Wang, Z | 1 |
| Li, Z | 1 |
| Lin, J | 1 |
| Wang, L | 1 |
| Yu, W | 1 |
| Zhang, Z | 1 |
| Viladés Medel, D | 1 |
| Leta Petracca, R | 1 |
| Carreras Costa, F | 1 |
| Cardona Olle, M | 1 |
| Barros Membrilla, A | 1 |
| Hidalgo Perez, JA | 1 |
| Pujadas Olano, S | 1 |
| Alomar Serrallach, X | 1 |
| Franco Peral, M | 1 |
| Pons-Lladó, G | 1 |
3 other studies available for iohexol and Apolipoprotein B-100, Familial Defective